AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
After-Hours Gainers: Biotech and Med-Tech Stocks Surge on FDA Signals, Clinical Data, and Merger News
ByAinvest
Tuesday, Dec 16, 2025 12:28 am ET1min read
Several biotech and med-tech stocks surged in Monday's after-hours session, driven by regulatory progress, clinical-data visibility, and merger-related developments. Organogenesis Holdings (ORGO) rose over 11% after completing a planned Type-B meeting with the FDA, while IO Biotech (IOBT) edged higher on published trial data. STAAR Surgical (STAA) climbed over 4% after Institutional Shareholder Services revised its stance on the company's pending merger with Alcon. ClearPoint Neuro (CLPT) and EUDA Health (EUDA) also gained over 9% despite no company-specific news.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet